Dendritic cells expressing a combined PADRE/MUC4-derived polyepitope DNA vaccine induce multiple cytotoxic T-cell...

Area of Science:

• Immunology
• Oncology
• Vaccine Development

Background:

• Mucin4 (MUC4) is a tumor-associated antigen overexpressed in various epithelial cancers.
• This overexpression presents MUC4 as a potential target for broad-spectrum cancer vaccine therapies.

Purpose of the Study:

• To create and evaluate a dendritic cell (DC)-based vaccine engineered to target MUC4.
• To assess the vaccine's biological characteristics and in vitro immune activity.

Main Methods:

• Dendritic cells (DCs) were transduced with an adenovirus encoding the PADRE T-helper epitope and MUC4-specific epitopes (HLA-A1 and HLA-A2 restricted) to create rAd-pE-DCs.
• The morphology and surface marker expression (CD86, CD83, CD80, HLA-DR) of mature DCs were analyzed post-transduction.
• Lymphocyte cytotoxic responses were measured after priming with rAd-pE-DCs, rAd-GFP-DCs, or mock-transfected DCs.

Main Results:

• Adenovirus transduction did not alter the morphology of mature DCs.
• rAd-pE-DCs exhibited high expression of key DC maturation markers.
• Lymphocytes primed with rAd-pE-DCs demonstrated potent cytotoxic activity, unlike those primed with control vectors.

Conclusions:

• Dendritic cell transduction with an adenovirus encoding PADRE and MUC4 epitopes (rAd-pE-DCs) is a viable strategy.
• This approach shows potential for effective immunotherapy against MUC4-associated malignancies.